The Satellite Symposium at BSH 2022 provided expert insights into treatment options in WM, the emerging role of BTKis in WM, and BTKi-associated toxicities and their management.

Report on updates in the treatment of B-cell malignancies presented at ASH 2021.

BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up-to-date with the BeiGene hematology pipeline and clinical trials.

Zanubrutinib (BGB-3111) is a Bruton’s tyrosine kinase inhibitor (BTKi), currently being evaluated in a broad late-stage clinical trials program globally to treat various B-cell malignancies.

Report on targeted and immune-directed therapies in B-cell malignancies presented at ASCO, EHA and ICML 2021.